From the Editor

Give vasopressin to reduce bleeding in gynecologic surgery

Author and Disclosure Information

5 units, in a very dilute solution, is plenty



Surgery on the uterus often causes significant hemorrhage—violaceous blood welling ominously from open veins and scarlet blood squirting vigorously from transected arteries, raising the heart rate of patient and surgeon alike.

To reduce blood loss during an operation, gynecologic surgeons often take the preventive step of injecting a dilute solution of vasopressin into the uterus or cervix before they start the procedure. That practice is a sound one: In randomized clinical trials, injection of vasopressin has been demonstrated to reduce blood loss in several gyn surgical procedures, including myomectomy, hysterectomy, abortion, and conization.1-6

A persistent concern, however, is that injection of vasopressin is, occasionally, associated with bradycardia and cardiac arrest, especially if injection is made into a blood vessel inadvertently. An unresolved issue is identifying the optimal dilution and dose of vasopressin that will reduce blood loss and minimize the risk of cardiac arrest.

Vasopressin is effective at reducing blood loss

As I noted, clinical trials have shown that vasopressin reduces blood loss during several gyn surgical procedures (see “Vasopressin is a uterotonic in the nonpregnant uterus,”). Two studies of interest looked at:

Pregnancy termination. 337 pregnant women undergoing termination of pregnancy were randomized to preprocedure injection into the cervix of either 20 mL of 1% mepivicaine solution or 4 units of vasopressin diluted (at 0.2 U/mL) in 1% mepivicaine. For women at 19 weeks’ gestation, or later, measured mean blood loss was 400 mL in the mepivicaine group and 179 mL in the vasopressin-mepivicaine group.4

Conization of the cervix. Ninety-two women undergoing conization were randomized to injection of saline or ≤3 units of vasopressin diluted in saline (0.1 U/mL) into the cervix.5 Blood loss averaged 136 mL in the saline group and 35 mL in the vasopressin-saline group.

Occasionally, there is associated bradycardia and cardiac arrest

In gynecologic surgery, bradycardia with subsequent cardiac arrest is a frightful and shocking development.

Cautionary case

Consider the report of a laparoscopic myomectomy,7 during which 11.2 units of vasopressin was injected into the myometrium at a dilution of 0.2 units/mL. Two minutes after injection, the patient’s heart rate fell to 58 bpm, then to 35 bpm; cardiac arrest followed—all in 5 minutes.

The patient was given 1 mg epinephrine, 0.5 mg of atropine, and 100% oxygen; chest compressions were initiated. Effective cardiac activity was reestablished. The heart rate was initially measured at 150 bpm; blood pressure, 220/140 mm Hg. Both vital signs gradually returned to normal range.

The surgical procedure was discontinued.

What might have caused these events?

It’s thought that a vasopressin-induced increase in blood pressure causes a vagal-mediated decrease in the heart rate. The vasoconstrictive effects of vasopressin may, simultaneously, cause coronary artery vasospasm, resulting in cardiac ischemia.

In many of the case reports of vasopressin-induced bradycardia and cardiac arrest, the dose of vasopressin administered, as in the case just described, exceeded 5 units,8,9 or the vasopressin was injected into a vessel unintentionally.10

The optimal dose and dilution of vasopressin continues to be controversial.

Vasopressin is a uterotonic in the nonpregnant uterus

The fraternal twins oxytocin and vasopressin are both secreted from the posterior pituitary gland. Both are nanopeptides that differ only in two amino acids.

Oxytocin binds to a myometrial cell-surface oxytocin receptor, thus increasing concentrations of intracellular cyclic adenosine monophosphate (cAMP), resulting in uterine contractions.

Vasopressin regulates plasma volume, blood pressure, and osmolality. It causes vasoconstriction by acting through the vasopressin (V1) receptor and exerts its antidiuretic action through the V2 receptor in the kidney. The major mechanism by which vasopressin reduces blood loss is vasoconstriction.

Vasopressin also stimulates uterine contractions by acting through myometrial V1a receptors. Unlike oxytocin receptors, which are plentiful in the term uterus but far less abundant in the nonpregnant uterus, vasopressin receptors are present in the myometrium of both pregnant and nonpregnant women.1

Administering vasopressin to nonpregnant women can therefore induce uterine contractions and the symptom of dysmenorrhea. A vasopressin antagonist will attenuate those effects.2


1. Wing DA, Goharkhay N, Felix JC, Rostamkhani M, Naidu YM, Kovacs BW. Expression of the oxytocin and V1a vasopressin receptors in human myometrium in differing physiologic states and following misoprostol administration. Gynecol Obstet Invest. 2006;62(4):181-185.

2. Liedman R, Grant L, Igidbashian S, James I, McLeod A, Skillern L, Akerlund M. Intrauterine pressure, ischemia markers, and experienced pain during administration of a vasopressin V1a receptor antagonist in spontaneous and vasopressin-induced dysmenorrhea. Acta Obstet Gynecol Scand. 2006;85(2):207-211.

What is an optimal dose and dilution?

Sparse high-quality data guide the selection of an optimal dosage and dilution of vasopressin. But, as with most pharmacotherapeutic agents that produce adverse effects at a high dosage, it is often wise to use the lowest that is efficacious.11 The clinical literature suggests several guidelines that may help reduce the likelihood and severity of adverse effects of vasopressin (see “Using vasopressin? Reduce the risk of adverse effects with these procedural tips,”).

Next Article: